Coriolis Pharma and U-Medico Announce a Strategic Alliance
Martinsried-Munich, Germany / Osaka, Japan / 18 March 2022 – Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs located in Germany, and U-Medico, an innovative formulation development and biophysical characterizations service provider located in Japan, today announce a strategic alliance that includes an equity investment by Coriolis Pharma into U-Medico.
The alliance aims to extend Coriolis Pharma’s expertise, service portfolio and market reach into the Japanese and Asian market, while strengthening U-Medico’s formulation development and biophysical characterization services, as well as expertise by giving integrated access to Coriolis Pharma’s service portfolio. Together, Coriolis Pharma and U-Medico will work on development projects for clients and enable innovative therapies by revolutionizing formulation development and biophysical characterizations of biopharmaceuticals and ATMPs, such as viral vectors, and gene- and cell therapies for clients worldwide.
In addition, researchers from both companies will exchange scientific knowledge and work together in scientific collaborations, to generate know-how and publications in the field of formulation development and characterization of biopharmaceuticals and gene- and cell therapy products.
“U-medico is the leading provider of science-driven formulation development and biophysical characterization services in Japan and we as Coriolis are proud to become part of it. The strategic alliance is the next step for Coriolis Pharma growths strategy based on excellent science.” said Dr. Michael Wiggenhorn, CEO of Coriolis Pharma.
Prof. Dr. Susumu Uchiyama, founder and Chief Scientific Officer of U-Medico, already joined the scientific advisory board of Coriolis Pharma in September 2021. Prof. Dr. Uchiyama is also leading the Japanse national project consortium for the development of characterization and quality control of virus vectors for gene therapy.
“This strategic alliance strengthens the scientific collaboration between Coriolis and U-Medico. We are excited to grow together and support our clients with more specialized and high-quality formulation development services,” pointed out by Dr. Ayano Fukuhara, CEO of U-Medico.
“In-depth biophysical chemistry knowledge based on high-quality science is essential for the characterizations of biopharmaceuticals and virus vectors. This alliance will definitely contribute to the development of biopharmaceuticals and ATMPs with high quality and safety,” said Prof. Dr. Susumu Uchiyama
About Coriolis Pharma:
Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advance therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma offers integrated development services for liquid and lyophilized formulations with all required technologies and analytical methods available in house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma supports all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Our motivation is to enable the development of innovative drugs by performing outstanding biopharmaceutical research to improve the quality of life for humankind.
U-Medico Inc., a spin-out contract research organization of Osaka University, offers high-quality formulation development services and unique analytical services, e.g., analytical ultra-centrifugation (AUC) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) for biopharmaceuticals including antibody and fusion proteins. U-Medico supports clients to produce safe and reliable biopharmaceuticals utilizing cutting-edge know-how and analytical technology. The company will establish a new unit for cell and gene therapy in April 2022 and intensively provide a high level of global standard analytical and quality testing services for gene therapy based on the expertise from Osaka University. Find out more under www.u-medico.co.jp